

*Supplementary Files***Table I.** The comparison of clinical presentations between the two genders.

Clinical presentation	Gender of the patients %(no)		<i>p</i> -value
	Female	Male	
Constitutional Symptoms	41.36 (194)	40.63 (26)	0.91
Skin Involvement (except skin thickening)	64.47 (303)	65.5 (40)	0.87
Vascular Involvement	68.87 (323)	62.5 (40)	0.30
GI Involvement	69.08 (324)	67.19 (43)	0.75
Pulmonary Involvement	58.21 (273)	46.88 (30)	0.08
Renal Involvement	7.89 (37)	15.63 (10)	0.04**
Cardiac Involvement	26.36 (133)	25 (16)	0.57
Neuromuscular Involvement	17.31 (81)	10.94 (7)	0.19
Musculoskeletal Involvement	54.37 (255)	51.58 (33)	0.67
Endocrine	15.57 (73)	12.5 (8)	0.52
Anemia	48.57 (220)	36.07 (22)	0.06

significant *p*-value (<0.05).Table II.** Causes of hospital admissions and their prevalences.

Hospitalization's reason	Percentage%	Number/687
Digital ulcer	30.9	212
Interstitial lung disease	5.7	39
Pulmonary hypertension	3.1	21
Pleural effusion	0.7	5
Pneumonia	2.9	20
Pulmonary emboli	0.1	1
Cardiac involvement	1.0	8
Tamponed	0.4	3
Corpulmonale	0.1	1
GI complication	5.2	36
Dysphagia	0.3	2
Skin nodules	0.1	1
Arthralgia	7.9	54
Septic Arthritis	0.1	1
Osteomyelitis	0.9	6
Weakness	5.8	40
Lower extremities edema	0.7	5
Fatigue and malaise	0.4	3
Generalized body pain	1.3	9
Myalgia	0.3	2
Hyperkeratosis	0.1	1
Raynaud	3.8	26
Vascular involvement except Raynaud	5.1	35
Renal crisis	2.3	16
Anemia	0.7	4
Drug receiving	5.1	35
Not definitely confirmed	5.4	37
Others	9.3	64

Table III. Full version of the comparison of clinical manifestations between three types of the disease.

Clinical Presentation	The frequency of presentations in various type (% , no)			P-value (3groups)	P-value (two by two comparison)		
	Diffused	Limited	Overlap SX		D ¹ vs L ²	L vs O ³	D vs O
Constitutional symptom	44.0% (89/202)	35.2% (69/196)	51.0% (47/92)	0.027**	NS	0.014	NS
1.Fatigue	11.8% (24/202)	9.6% (19/196)	18.4% (17/92)	0.103	NS	0.054	NS
2.Stiff joints	14.8% (30/202)	10.7% (21/196)	18.4% (17/92)	0.180	NS	NS	NS
3.Pain	24.7% (50/202)	19.8% (39/196)	28.2% (26/92)	0.252	NS	NS	NS
4.Sleep difficulties	66.7% (2/202)	0.0%	33.3% (1/92)	0.364	NS	NS	NS
Skin involvement	59.4% (120/202)	73.9% (145/196)	64.1% (59/92)	0.008**	0.002	NS	NS
1.Skin discoloration	13.8% (28/202)	8.1% (16/196)	14.1% (13/92)	0.147	NS	NS	NS
2.prunitis	11.3% (23/202)	8.1% (16/196)	10.8% (10/92)	0.537	NS	NS	NS
3.sclerodactyly	26.7% (54/202)	26% (51/196)	23.9% (22/92)	0.877	NS	NS	NS
4.digital ulcer	39.6% (80/202)	47.9% (94/196)	22.8% (21/92)	<0.0001**	NS	<0.001	0.005
5.pitting at fingertips	8.9% (18/202)	10.7% (21/196)	9.7% (9/92)	0.833	NS	NS	NS
6. Telangiectasia	11.3% (23/202)	16.3% (32/196)	3.2% (3/92)	0.006**	NS	0.01	0.026
7.calcinosis cutis	4.9% (10/202)	4% (8/196)	2.1% (2/92)	0.537	NS	NS	NS
Vascular involvement	63.3% (128/202)	75% (147/196)	68.4% (63/92)	0.04**	0.013	NS	NS
1.raynaud	61.8% (125/202)	73.4% (144/196)	68.4% (63/92)	0.046**	0.014	NS	NS
2.digital pitting scar	5.4% (11/202)	4% (8/196)	2.1% (2/92)	0.431	NS	NS	NS
3.digital gangrene	7.9% (16/202)	6.6% (13/196)	3.2% (3/92)	0.324	NS	NS	NS
4.digital tip ulcer	6.4% (13/202)	8.6% (17/196)	4.3% (4/92)	0.370	NS	NS	NS
GI involvement	78.2% (158/202)	59.1% (116/196)	66.3% (61/92)	<0.0001**	<0.0001	NS	0.043
1.dysphagia	33.1% (67/202)	22.4% (44/196)	29.3% (27/92)	0.057	NS	NS	NS
2.sicca syndrome	4.9% (10/202)	4% (8/196)	6.5% (6/92)	0.670	NS	NS	NS
3.reflux	67.8% (137/202)	50.5% (99/196)	48.9% (45/92)	<0.0001**	0.001	NS	0.003
4.reflux esophagitis	5.4% (11/202)	3% (6/196)	8.6% (8/92)	0.123	NS	NS	NS
5.abnormal motility of esophagus	3.9% (8/202)	1% (2/196)	2.1% (2/92)	0.162	NS	NS	NS
6.full stomach	2.4% (5/202)	0.5% (1/196)	1% (1/92)	0.244	NS	NS	NS
7.vomiting	12.3% (25/202)	3.5% (7/196)	11.9% (11/92)	0.004**	0.001	0.009	NS
8.gastritis	1.9% (4/202)	0.5% (1/196)	8.6% (8/92)	<0.0001**	NS	0.001	0.011
9.malabsorption	0.0%	0.0%	1% (1/92)	0.114	NS	NS	NS
10.diarrhea	13.8% (28/202)	6.1% (12/196)	8.6% (8/92)	0.032**	0.012	NS	NS
11.constipation	14.8% (30/202)	66.3% (13/196)	8.6% (8/92)	0.023**	0.01	NS	NS
12.mixed diarrhea and constipation	3.9% (8/202)	1% (2/196)	3.2% (3/92)	0.175	NS	NS	NS
13.primary biliary cirrhosis	0.0%	1% (2/196)	0.0%	0.222	NS	NS	NS
14.chronic cholestasis liver disease	0.0%	0.5% (1/1)	0.0%	0.472	NS	NS	NS
15.pancreatitis	0.5% (1/1)	0.0%	0.0%	0.490	NS	NS	NS
Pulmonary involvement	77.7% (157/202)	42.3% (83/196)	46.7% (43/92)	<0.0001**	<0.0001	NS	<0.001
1.ILD	70.7% (143/202)	37.7% (74/196)	39.2% (36/92)	<0.0001**	<0.001	NS	<0.001
2.pulmonary hypertension	22.7% (46/202)	8.6% (17/196)	7.6% (7/92)	<0.0001**	0.0001	NS	0.02
3. Pleural effusion	3.9% (8/202)	0.5% (1/196)	4.3% (4/92)	0.055	0.037	0.038	NS
Renal involvement	12.3% (25/202)	3% (6/196)	13% (12/92)	0.001**	0.001	0.03	NS
1.renal crisis	4.4% (9/202)	0.5% (1/196)	1% (1/92)	0.021	0.02	NS	NS
2.renal failure	5.4% (11/202)	0.5% (1/196)	3.2% (3/92)	0.017**	0.006	NS	NS
Cardiac involvement	33.6% (68/202)	17.3% (34/196)	31.5% (29/92)	0.001**	<0.001	0.009	NS
1. Pericardial involvement	15.8% (32/202)	3% (6/196)	14.1% (13/92)	<0.0001**	<0.001	0.001	NS
2.myocardial involvement	13.3% (27/202)	2.5% (5/196)	13% (12/92)	<0.0001**	<0.001	0.001	NS
3.valvular disease	18.3% (37/202)	7.6% (15/196)	17.3% (16/92)	0.005**	0.002	0.023	NS
4.arrythmia	1.4% (3/202)	0%	0%	0.117	NS	NS	NS
Musculoskeletal	58.4% (118/202)	42.8% (84/196)	72.8% (67/92)	<0.0001**	0.003	<0.0001	0.019
1. Arthralgia	29.7% (60/202)	29% (57/196)	45.6% (42/92)	0.011**	NS	0.008	0.009
2.myalgia	2.9% (6/202)	3.5% (7/196)	7.6% (7/92)	0.158	NS	0.008	0.001
3.weakness	18.8% (38/202)	13.7% (27/196)	36.9% (34/92)	<0.0001**	NS	<0.0001	NS
4.arthritis	4.4% (9/202)	4% (8/196)	6.5% (6/92)	0.645	NS	NS	NS
5.edema	14.3% (29/202)	7.6% (15/196)	17.3% (16/92)	0.031**	0.038	0.023	NS
Neuromuscular involvement	13.8% (28/202)	12.7% (25/196)	32.6 (30/92)	<0.0001**	NS	<0.001	<0.0001
1.neuropathy	8.4% (17/202)	8.1% (16/196)	18.4% (17/92)	0.014**	NS	0.016	0.018
2.myopathy	2.4% (5/202)	2.5% (5/196)	9.7% (9/92)	0.005**	NS	0.015	0.014
3.myositis	1.4% (3/202)	1.5% (3/196)	8.6% (8/92)	0.001**	NS	0.006	0.005
Genitourinary involvement	3.9% (8/202)	3% (6/196)	8.6% (8/92)	0.088	NS	NS	NS
Endocrine involvement	16.3% (33/202)	11.7% (23/196)	21.7% (20/92)	0.084	NS	0.033	NS
1.Hypothyroidism	8.4% (17/202)	5.6% (11/196)	9.7% (9/92)	0.381	NS	NS	NS
2.Hyperthyroidism	0.4% (1/202)	1.5% (3/196)	1% (1/92)	0.588	NS	NS	NS
3. Diabetes	6.4% (13/202)	3.5% (7/196)	9.7% (9/92)	0.105	NS	0.05	NS
Anemia	48.7% (95/195)	37.7% (74/184)	55.4% (51/92)	0.044**	NS	0.021	NS

**Significant *p*-value (<0.05). NS: Non-Significant. 1.D: diffused form of scleroderma; 2.L: limited form of scleroderma; 3.O: overlap syndrome.